Schering-Plough (SGP) Files Patent Infringement Suit Against GeoPharma (GORX)
More News related to GORX
- GeoPharma Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement
- GeoPharma (GORX) Reports a Q1 Loss
- GeoPharma (GORX) Announces Strategic Restructuring Plan
- GeoPharma (GORX) Adds India, Nepal, Bangladesh, Sri Lanka and South Korea as New Distribution Channels for Mucotrol(TM)
- GeoPharma (GORX) Receives Receives FDA Approval for Carprofen
More News related to SGP
- "AIM"ING FOR BETTER ASTHMA CARE
- Merck and Schering-Plough to Complete Merger Today
- Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
- Schering-Plough Announces Sponsorship of Rabies-Control Projects in India
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
GeoPharma, Inc. (Nasdaq: GORX) announced that Schering-Plough (NYSE: SGP), has filed a lawsuit against the Company and its wholly owned subsidiary, Belcher Pharmaceuticals, Inc. in the United States District Court, District of New Jersey (No. 3:06-cv-04715-MLC-TJB), alleging patent infringement related to Belcher's filing for a generic version of Clarinex Desloratadine 5 mg tablets.
According to the complaint, the other defendants are alleged to have filed their ANDA's and Paragraph IV certifications on the same day as Belcher, June 21, 2006. Schering Plough markets Clarinex (R) for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, chronic idiopathic urticaria. According to Schering-Plough, U.S. sales of Clarinex for 2005 were $325 million.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
